Journal of Gynecology & Reproductive Medicine(JGRM)
ISSN: 2576-2842 | DOI: 10.33140/JGRM
Impact Factor: 1.247
Dr. Saurav Prakash Maityr
Medical Director, Rashmika Fertility, India
Publications
-
Research Article
ELOGA-IVF STUD: Comparative Effectiveness of Oral Elagolix Once Daily, Oral Elagolix Twice Daily, and Injectable Cetrorelix During Controlled Ovarian Stimulation in GnRH Antagonist IVF Cycles: A Retrospective Cohort Study
Author(s): Dr. Saurav Prakash Maityr* and Dr. Apurba Pailan
Background GnRH antagonists are routinely used during controlled ovarian stimulation (COS) to prevent premature luteinizing hormone (LH) surge. Injectable Cetrorelix is the conventional antagonist; however, oral elagolix has emerged as a potential alternative because of easier administration and lower treatment burden. Comparative real-world evidence remains limited. Objective To compare ovarian stimulation, embryological, and clinical outcomes among women receiving injectable Cetrorelix, oral elagolix 200 mg twice daily, and oral elagolix 200 mg once daily during antagonist IVF cycles. Methods A retrospective observational cohort study was conducted at Rashmika Fertility, Kolkata, India. Medical records of women undergoing antagonist IVF cycles between January 2024 and December 2025 were reviewed. Patients were ca.. Read More»